CDKN2A and melanoma: The results demonstrated that deletion of chromosome 15q, including B2M, caused loss of PTEN and cyclin-dependent kinase inhibitor 2A (CDKN2A) homozygous deletion was observed in the resistance to immunotherapy in melanoma patients [30].